Glucose metabolism in brain tumours: comparing glucoCEST MRI with [18F]FDG-PET
- Conditions
- tissues and organs10027476
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
• Age >= 18 years
• Primary intra-axial brain tumour of any type or secondary brain tumour (brain
metastases) of any solid tumour
• Signed and dated written informed consent form prior to any study-specific
procedures
• WHO performance status of 0 or 1
• Glucose- and/or FDG-infusion related exclusion criteria:
o Uncontrolled Diabetes Mellitus type 1 or 2 (requiring fast-acting insulin)
o Uncontrolled tonic-clonic seizures (>1 per month despite anti-epileptic
treatment)
• Not being able to undergo contrast enhanced MR scans or [18F]FDG-PET exam (in
line with local protocol13):
o Pacemaker, mechanic heart valve, blood vessel prosthetic, stent or coil
incompatible with MR scanning
o Metal in eyes (splinters, from surgery), ears (hearing aid) or on the body
where it cannot be removed (e.g. insulin pump, piercings)
o Dental prosthesis with magnetic system
o Breastfeeding
o Pregnancy
o Claustrophobia
o Known anaphylactic reaction to [18F]FDG or gadolinium-based contrast agents
• Severe blood iron deficiency (with haemoglobin concentration <6.0mmol/L)
• History of severe renal disease/renal transplant, or an eGFR (MDRD)
<30mL/min/1,73m2
• Has any medication that decreases the chances of obtaining reliable data and
achieving the study objectives
• History of somatic or psychiatric disease/condition that may interfere with
the objectives and assessments of the study
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>GlucoCEST signal of pre-, during and post-glucose bolus injection values,<br /><br>standardized uptake value (SUV), signal-to-noise-ratio (SNR),<br /><br>contrast-to-noise-ratio (CNR), tumour volume, tumour perfusion</p><br>
- Secondary Outcome Measures
Name Time Method <p>N/A</p><br>